Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1150 MG double-blinded secukinumab----1件: 271 💬
2150 MG OPEN-label secukinumab----1件: 271 💬
3300 MG double-blinded secukinumab----1件: 271 💬
4Secukinumab1件: Secukinumab (Secukinumab)1件: Secukinumab (Secukinumab, Secukinumab) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
5Secukinumab 150 MG1件: Secukinumab (Secukinumab)1件: Secukinumab (Secukinumab, Secukinumab) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 41 💬
6Secukinumab 150 MG (2 injections PER dose1件: Secukinumab (Secukinumab)1件: Secukinumab (Secukinumab, Secukinumab) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 269 💬
7Secukinumab 150 MG/1 ML solution FOR injection1件: Secukinumab (Secukinumab)1件: Secukinumab (Secukinumab, Secukinumab) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬2件: 37, 271 💬
8Secukinumab 150 MG/ML1件: Secukinumab (Secukinumab)1件: Secukinumab (Secukinumab, Secukinumab) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271 💬
9Secukinumab 150MG1件: Secukinumab (Secukinumab)1件: Secukinumab (Secukinumab, Secukinumab) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 37 💬
10Secukinumab 300 MG1件: Secukinumab (Secukinumab)1件: Secukinumab (Secukinumab, Secukinumab) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 41 💬
11Secukinumab 300MG1件: Secukinumab (Secukinumab)1件: Secukinumab (Secukinumab, Secukinumab) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 37 💬
12Secukinumab 75 MG/0.5 ML solution FOR injection1件: Secukinumab (Secukinumab)1件: Secukinumab (Secukinumab, Secukinumab) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271 💬
13Secukinumab injection1件: Secukinumab (Secukinumab)1件: Secukinumab (Secukinumab, Secukinumab) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 160 💬